Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-380-250"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"de"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-380-250"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-380-3752
lpv:speaker	lp:Franz Obermayr2
lpv:spokenAs	member; Delegation for relations with the Mashreq countries (2012-02-13--2014-06-30)3 substitute; EMPL (2012-01-19--2014-06-30)3 member; IMCO (2012-01-19--2014-06-30)3 member; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2012-03-29--2014-06-30)3 substitute; Delegation to the EU-Kazakhstan, EU-Kyrgyzstan and EU-Uzbekistan Parliamentary Cooperation Committees, and for relations with Tajikistan, Turkmenistan and Mongolia (2009-09-16--2014-06-30)3 unknown; Freiheitliche Partei Österreichs (2009-07-14--2014-06-30)3 member; NA (2009-07-14--2014-06-30)3
lpv:translated text	"I welcome any measures that could further strengthen the pharmacovigilance system at EU level and thus lead to the minimisation of risk for patients. Patient safety must be our top imperative. It is absolutely necessary that we continue to monitor medicines after their marketing approval because, after all, they are only trialled on a relatively small number of patients. New insights into safety often arise only after prolonged periods of use. In view of the proposed amendment of the Pharmacovigilance Directive 2001/83/EC, I welcome the report and have voted in favour of it."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph